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Rehovot, IsraelABSTRACT Electron microscopy structural determinations suggest that the membrane-proximal external region (MPER) of
glycoprotein 41 (gp41) may associate with the HIV-1 membrane interface. It is further proposed that MPER-induced disruption
and/or deformation of the lipid bilayer ensue during viral fusion. However, it is predicted that the cholesterol content of this
membrane (~45 mol %) will act against MPER binding and restructuring activity, in agreement with alternative structural models
proposing that the MPER constitutes a gp41 ectodomain component that does not insert into the viral membrane. Here, using
MPER-based peptides, we test the hypothesis that cholesterol impedes the membrane association and destabilizing activities of
this gp41 domain. To that end, partitioning and leakage assays carried out in lipid vesicles were combined with x-ray reflectivity
and grazing-incidence diffraction studies of monolayers. CpreTM, a peptide combining the carboxyterminal MPER sequence
with aminoterminal residues of the transmembrane domain, bound and destabilized effectively cholesterol-enriched mem-
branes. Accordingly, virion incubation with this peptide inhibited cell infection potently but nonspecifically. Thus, CpreTM seems
to mimic the envelope-perturbing function of the MPER domain and displays antiviral activity. As such, we infer that CpreTM
bound to cholesterol-enriched membranes would represent a relevant target for anti-HIV-1 immunogen and inhibitor
development.INTRODUCTIONCell infection by the human immunodeficiency virus type-1
(HIV-1) begins with the merger of viral and cellular
membranes by the envelope glycoprotein transmembrane
subunit (gp41) (1,2). The membrane-proximal external
region (MPER) of gp41 is enriched in conserved aromatic
residues and is required for fusogenic activity (3,4)
(Fig. 1). Cryoelectron microscopy and 3D reconstructions
of intact virions and detergent-solubilized glycoproteins
display each trimer’s stalk as composed of three legs that
project obliquely from the trimer head, tripodlike, and insert
independently through the MPER into the external mono-
layer of the viral membrane (5,6) (Fig. 1 A, left). Supporting
the relevance of this interfacial structure, hydrophobicity
distribution and structural analyses suggest that the MPER
favorably inserts into the water-bilayer interface as an
a-helix that runs almost parallel to the membrane plane
(7–9). Recent mutational studies further indicate that inser-
tion of the MPER and the adjacent transmembrane domain
(TMD) stretch may disrupt the membrane during gp41-
induced fusion (10,11).
In contrast to this view, a competing model postulates that
MPER remains associated to the native gp41 ectodomain
stalk region, i.e., without establishing contacts with the viral
membrane (12,13) (Fig. 1 A, right). In addition, interactions
of this element with the viral membrane are not consideredSubmitted May 6, 2011, and accepted for publication October 12, 2011.
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0006-3495/11/11/2426/10 $2.00at any stage of the fusion mechanism (14). This model is
supported by the presence of high cholesterol (Chol)
concentration at the viral envelope (~45 mol % (15)). This
Chol concentration corresponds to that of a highly ordered
membrane domain, and precludes coexistence with laterally
segregated, more fluid domains (15). Lorizate et al. (16)
actually determined for infectious virions lipid order levels
at 37C corresponding to those found in liquid-ordered (lo)
domains. In general, high levels of Chol exert a phospholipid
condensing effect that hinders water-membrane partitioning
and subsequent assembly of lytic pores by peptides that bind
tightly to the membrane interface (17,18), as is predicted to
be the case for MPER (7). Accordingly, Chol interferes with
the membrane-interacting properties of antimicrobial, cyto-
lytic, and cell-penetrating peptides such as magainin (19),
gramicidin S (20), cathelicidin LL-37 (21,22), melittin
(17,23), or transportan (24), although exceptions to this
general rule can be found in the literature (25,26). In addi-
tion, certain cytolytic peptides, such as d-lysin, are mostly
excluded from Chol-enriched ordered domains in systems
that exhibit separation between liquid-disordered (ld) and
lo domains (27,28). Thus, despite MPER hydrophobicity,
the Chol concentration existing at the viral membrane would
likely preclude MPER-membrane binding and subsequent
restructuring activity.
To test this hypothesis, in this work, we investigate
the effects of biologically relevant Chol concentrations
on MPER-membrane interactions. To that end, first, we
compare the membrane-binding and lytic activities of twodoi: 10.1016/j.bpj.2011.10.005
FIGURE 1 Models for gp41 MPER-TMD region organization at the HIV
membrane and designation of the CpreTM and MPERp sequences used in
this study. (A) Proposed models for the location of gp41 MPER-TMD at the
Chol-enriched viral membrane. The cryoET density map contours of enve-
lope spikes reported by Zhu et al. (5) and Zanetti et al. (12) are compared
(left and right gray areas, respectively). Sequences depicted roughly
parallel to the membrane plane (left) span amphipathic-at-interface and
interfacial MPER subdomains (7). Cylinders inserted into the membrane
represent the TMD anchors. (B) Sequences of the peptides used in this
study. The diagram also shows positions and sequences for the potential
cholesterol recognition/interaction amino acid consensus (outlined residue
sequence) and 4E10 epitope (underlined residues). Sequence and
numbering are according to the prototypic HXBc2 isolate.
FIGURE 2 Effect of Chol on the lytic activities and binding capacities of
MPER peptides. (A, left) Effect of Chol on CpreTM-induced leakage
kinetics. The peptide was added at the time indicated by the arrow (t ¼
50 s) at a peptide/lipid ratio of 1:500. Lipid concentration was 100 mM.
Chol mole fractions are indicated for each curve. (A, right) Partitioning
curves estimated from the fractional change in Trp fluorescence with
increasing POPC or POPC/Chol (1:1) concentrations (squares and circles,
respectively). Peptide concentration was 0.5 mM. Lines correspond to the
best fit of the experimental values to a hyperbolic function (see Materials
and Methods in the Supporting Material). (B) MPERp peptide was used
at a peptide/lipid ratio of 1:150 in the leakage assays (left). Otherwise,
conditions are as in A.
MPER Activity Dependence on Cholesterol 2427overlapping, MPER-based peptides as a function of the Chol
content in lipid vesicles (Fig. 1 B): MPERp, representing
the sequence characterized in previous structural studies
(9) and currently targeted by anti-MPER vaccines (29);
and CpreTM, a peptide designed to preserve the sequence
environment of the MPER-TMD hinge, which embodies
an important gp41 functional determinant (4,11,30). Our
data suggest that the sequence represented by MPERp (so
far considered the canonical MPER peptide) would be inca-
pable of perturbing the Chol-enriched viral envelope. In
contrast, CpreTM bound to and permeabilized effectively
vesicles containing Chol levels comparable to those existing
at the viral envelope. Consistent with its potential for per-
turbing the viral membrane, CpreTM inhibited cell-assem-
bled enveloped virions potently but nonspecifically. X-ray
diffraction analyses of lipid monolayers containing the
peptide, together with previously reported biophysical data
on the short LWYIK oligopeptide (31,32), provided molec-
ular mechanisms for the interactions of CpreTM with Chol-
enriched membranes. Our results support the physiological
relevance of membrane-bound states of the MPER sequencerepresented by CpreTM, and the capacity of this gp41
domain to destabilize the viral lipid-bilayer architecture
during fusion. Hence, we propose that the functional
MPER sequence should be redefined to include N-terminal
TMD residues. Finally, we discuss the implications of our
findings for the development of peptide-based vaccines
and inhibitors targeting MPER.MATERIALS AND METHODS
See the Supporting Material for the materials and methods used in this
work.RESULTS
Chol effects on the membrane-perturbing
properties of MPER-derived peptides
Mutational studies have established a correlation between
MPER lytic activity and gp41 fusogenic function (10).
The vesicle leakage kinetics reflect the lytic activities of
CpreTM and MPERp peptides (Fig. 2, A and B, left). In
consonance with the role proposed for the MPER domainBiophysical Journal 101(10) 2426–2435
2428 Apella´niz et al.during fusion, both peptides permeabilized vesicles devoid
of Chol. However, whereas CpreTM was capable of
inducing even higher levels of leakage from vesicles con-
taining 0.5 mole fraction of Chol (Fig. 2 A, left), MPERp
activity was markedly reduced in these vesicles (Fig. 2 B,
left). The high Chol levels correlate with increased bilayer
elastic moduli (33,34). The increase in the area compress-
ibility modulus (KA) induced by this compound has been
shown to reduce the capacity of peptides to transfer from
water into membranes (18). Thus, we first sought to estab-
lish a correlation between leakage and peptide-membrane
partitioning (Fig. 2, right, and Fig. S1 in the Supporting
Material). The lipid titration curves rendered comparable
apparent mole fraction partition coefficients for CpreTM in-
teracting with POPC and POPC/Chol (1:1) vesicles (Kx(app)
values of 6.5 106 and 5.5 106, respectively). In contrast,
as compared to POPC vesicles, the partitioning coefficient
was reduced by two orders of magnitude for MPERp inter-
acting with POPC/Chol (1:1) vesicles (Kx(app) values of
1.4  107 and 1.7  105, respectively).
To illustrate this observation further, data displayed in
Fig. 3 compare KA increase, peptide association to vesicles,FIGURE 3 Binding to vesicles and ANTS leakage induced by CpreTM
(upper) and MPERp (lower) as a function of the Chol mole fraction. Plotted
values correspond to leakage (extents measured 60 min after peptide addi-
tion) and binding to membranes relative to those measured for vesicles
devoid of Chol (solid and open circles, respectively). Dotted and dashed
curves indicate values of the area compressibility moduli as measured by
Needham and Nunn (33) and Henriksen et al. (34), respectively. Otherwise,
experimental conditions are as in Fig. 2.
Biophysical Journal 101(10) 2426–2435and resulting leakage as a function of the Chol content in
lipid vesicles. Chol did not appreciably affect CpreTM par-
titioning into membranes in the range of the tested concen-
trations (Fig. 3, upper, open symbols). In contrast, the
MPERp capacity for associating with the vesicles was
impaired above the onset of the KA increase (~0.2–0.3
mole fraction (33,34)) (Fig. 3, lower, open symbols). The
percentages of leakage induced by CpreTM and MPERp
peptides, as a function of Chol content, were also compara-
tively different. Below the onset of the KA increase,
CpreTM-induced vesicle permeabilization was enhanced
(Fig. 3, upper, solid symbols). This effect reached a maxi-
mum and began to decrease slightly at the onset of the KA
increase, but leakage was not inhibited. A comparable
behavior was reported for the cytolytic peptide d-lysin inter-
acting with Chol-containing vesicles (27,28). In contrast,
low levels of Chol barely affected MPERp-induced perme-
abilization (Fig. 3, lower, solid symbols). Above the onset
of the KA increase, leakage induced by this peptide was
inhibited.
In conclusion, Chol-induced KA increase correlated with
a reduction of MPERp binding to vesicles and the subse-
quent inhibition of its lytic activity. Since MPERp, and
closely related peptides, are considered to embody the
canonical MPER sequence (3,7,9), these results would be
consistent with the absence of interactions between this
gp41 domain and the viral membrane (Fig. 1 A, right).
However, the CpreTM data, i.e., binding and permeabiliza-
tion of vesicles containing Chol mole fractions >0.2–0.3,
indicate that the envelope-perturbing activity of the MPER
domain might be retained within this sequence. The
following results support this notion.Inhibition of viral infectivity by MPER-derived
peptides
Recent works describe the discovery and development of
antiviral compounds that inhibit cell infection by a broad
range of enveloped viruses (35,36). These compounds target
the viral membrane and are believed to alter its structural
and/or material properties. Therefore, to test the possibility
that CpreTM could perturb the lipid bilayer surrounding the
HIV particle, we evaluated its effect on HIV virion function-
ality (Fig. 4). We assumed that, given its limited capacity for
partitioning into viral membranes, MPERp would compara-
tively exert a lower effect on virus infectivity. However, the
MPERp peptide contains the NEQELLELDKWASLWNWF
sequence representing the C-terminal portion of the fusion
inhibitor T-20 and overall accounting for 50% of its resi-
dues. Thus, in principle, MPERp-induced infection inhibi-
tion, if any, was also expected to be more specific than
that exerted by CpreTM.
Results displayed in Fig. 4 confirmed our predictions.
Both peptides inhibited HIV infectivity as measured in the
pseudovirus assay (Fig. 4 A, circles and solid lines). From
FIGURE 4 Inhibition of viral infectivity induced by CpreTM and
MPERp. (A) Dose dependency of pseudovirus infection inhibition. Viruses
were pseudotyped with HIV-1 Env (HXB2) or VSV-G (solid and dotted
lines, respectively). The infection of TZM-bl target cells was monitored
in both cases by flow cytometry as the green fluorescent protein signal in
infected cells. (B) Specificity of the inhibitory effect. HIV-1 and VSV pseu-
dovirions (solid and open columns, respectively) were incubated with 5 mM
of CpreTM or MPERp. T-20 fusion inhibitor (0.1 mM) was included as
a positive control for HIV-1 specificity. The asterisk denotes p < 0.005
by Student’s test for unpaired data. Graphs in both panels display the
mean5 SD of four measurements in two independent experiments.
MPER Activity Dependence on Cholesterol 2429the dose-dependency curves, IC50 values on the order of 0.5
and 50 mM were inferred for CpreTM and MPERp, respec-
tively. For comparison, IC50 values in the range of 10 nM
were measured for the HIV-1 specific fusion inhibitor
T-20 in our assay (not shown). Peptide-induced inhibition
was also tested by pseudotyping the HIV particles with
the VSV-G-protein (Fig. 4 A, squares and dashed lines).
VSV-G-protein-mediated infection could be inhibited by
CpreTM to a comparable extent, whereas MPERp was
totally ineffective. Fig. 4 B illustrates the specificity of the
inhibitory activities. Significant differences between capac-
ities for inhibiting HIV or VSV pseudoviruses could be
observed for T-20 and MPERp, whereas CpreTM inhibited
both types of virions with equal potency.Mechanism of CpreTM-induced perturbation
of Chol-containing membranes
The lack of specificity observed in the previous experiments
supports the hypothesis that the virion membrane, rather
than the gp41 protein, is the target for CpreTM-induced
infection inhibition. The high content of aromatic residues
(Fig. 1 B) suggests that CpreTM could tightly bind to the
viral membrane interface and disrupt lipid packing accord-ing to an interfacial activity mechanism similar to that pro-
posed for antimicrobial peptides (AMPs) (10,37). Leakage
according to such a mechanism is usually observed to occur
in 100-nm large unilamellar vesicles (LUVs) at peptide/lipid
mole ratios in the vicinity of 1:100 or higher. By comparison,
in the case of true pore-forming peptides, a limited number
of monomers may establish an aqueous channel in a single
LUV, and the resulting leakage could be observed at
peptide/lipid ratios as low as 1:10,000 (37,38).
Thus, to test the CpreTM mode of action, we next deter-
mined the range of peptide/lipid ratios required to cause
leakage of Chol-enriched vesicles. Fig. 5 A illustrates
CpreTM partitioning into POPC, POPC/Chol (4:1), and
POPC/Chol (2:1) vesicles. Thewater-membrane partitioning
curves disclosed a similar capacity of the peptide for parti-
tioning into these vesicles, under the experimental conditions
selected for measuring leakage. In contrast, the effective
CpreTM doses required for vesicle permeabilization were
lower in the Chol-containing vesicles (Fig. 5 B and
Table S1). Thus, for the same amount of membrane-bound
peptide, pore formation was more efficient in the Chol-con-
taining vesicles. Again, comparable Chol effects have been
reported for leakage induced by the cytolytic peptide d-lysin
(27,28).
Finally, the requenching data shown in Fig. 5 C confirmed
that CpreTM-induced leakage in POPC, POPC/Chol (4:1),
and POPC/Chol (2:1) vesicles followed a similar all-or-
none mechanism. The goal of the requenching assay (39)
is to establish the dependence of the quenching inside vesi-
cles (Qin) on the ANTS fraction outside vesicles (fout). Qin is
defined as the ratio between the ANTS fluorescence inside
vesicles at any time (Fi) and its maximum possible value
in the absence of DPX (Fi
max). Qin remains constant and
low for any fout value when peptide-induced leakage follows
an all-or-none mechanism, i.e., the population of vesicles
consists of those that did not leak at all and those releasing
all of their aqueous contents. Consistent with vesicle perme-
abilization according to a well-defined all-or-none mecha-
nism, the CpreTM experimental Qin values were low and
constant for all compositions.
In summary, the low membrane doses required for per-
meabilizing POPC/Chol 2:1 vesicles (in the peptide/lipid
mole ratio range 1:10,000–1:1000) together with a defined
all-or-none mechanism of leakage would qualify CpreTM
as a true pore-forming peptide (37).CpreTM and lipid organization in fluid
phospholipid monolayers containing Chol
X-ray reflectivity (XR) and grazing-incidence x-ray diffrac-
tion (GIXD) studies of lipid monolayers containing CpreTM
sustained a membrane-perturbation mechanism dissimilar
to that of AMPs (Tables 1 and 2). Analysis of specular
XR data yields information on the electron density distribu-
tion in a monolayer in a direction perpendicular to theBiophysical Journal 101(10) 2426–2435
FIGURE 5 Dose dependency and mechanism of CpreTM-induced con-
tent leakage from POPC (circles and solid lines), POPC/Chol (4:1) (squares
and dotted lines), and POPC/Chol (2:1) (triangles and dashed lines) LUVs.
(A) Partitioning curves estimated from the fractional change in Trp fluores-
cence with increasing lipid concentration. The fitting curves are superim-
posed. (B) ANTS leakage (extent measured 60 min after peptide addition)
measured as a function of the peptide/lipid mole ratio. The lines link the
experimental values for better appreciation of the differences. (C) Fluores-
cence requenching analysis to establish themechanism ofmembrane perme-
abilization. Internal quenching (Qin) was measured as a function of the
ANTS released (fout) after incubationwith peptide (see SupportingMaterial).
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over ordered and disordered regions of the film. Changes
in r(z) after introduction of CpreTM can be related to the
depth of membrane insertion, orientation within a film,
and interfacial concentration (lipid/peptide ratio) of the
peptide. On the other hand, the membrane-disruptive
activity of the peptide can be assessed with GIXD, which
provides direct structural information on a nanoscale lateral
molecular order in Langmuir monolayers. Consequently,
these techniques were chosen to investigate at the molecular
level the Chol effects on CpreTM-lipid interactions and de-
stabilizing activity, which are not derived from changes in
the elastic properties of the bilayers. Thus, experiments
were carried out on planar phospholipid monolayers with
low and high levels of Chol with and without the peptide
(Tables 1 and 2).
Using constant-pressure insertion assays, we first tested
the propensity of CpreTM to incorporate into DPPC/choles-
terol (87:13 and 54:46) mixed monolayers at a constant
surface pressure of 20 mN/m. The final relative increase
in mean molecular area, DA/A, upon introduction of
CpreTM comprised 14% in the 87:13 DPPC/cholesterol
monolayer and 26% in the 54:46 DPPC/cholesterol film.
Table 1 summarizes the results of our analysis of XR data
from monolayers before and after introduction of CpreTM.
Reflectivity curves giving rise to those data are shown in
Fig. S2. In a recent x-ray study (40), it was shown that
DPPC/cholesterol monolayers can be approximated by
a three-slab system, where each of the slabs is characterized
by an individual electron density (ri) and thickness (Li)
(Table 1). The top slab (closest to the air) contains the
acyl chain (AC) of cholesterol molecule and a portion of
DPPC acyl chains. The middle slab includes the rest of
the DPPC acyl chains and the cholesterol rigid-ring body
structure (RB), and the bottom slab (closest to the aqueous
buffer) represents DPPC and cholesterol headgroups
(HGs). The packing density of the hydrophobic core of
87:13 DPPC/cholesterol mixture is lower than that of the
54:46 mixture, as follows from the corresponding electron
densities/unit area of 4.94 e/A˚2 and 5.66 e/A˚2, respec-
tively. Although the electron density/unit area of the HGs
of the 87:13 DPPC/cholesterol mixture, 3.77 e/A˚2, is
25% higher than that of the 54:46 mixture, 2.96 eA˚2, this
is mainly due to the difference in hydration between the
HGs in two monolayers (3.6 vs. 2.9 water molecules/lipid
HG). Therefore, we anticipate that the peptide should incor-
porate with similar propensity into the HGs of the 54:46 and
87:13 mixtures, but the hydrophobic core of the 54:46
mixed monolayer should represent a more challenging
barrier to peptide penetration.
However, the reflectivity data for the lipid monolayer/
peptide systems revealed similar degrees of CpreTM pene-
tration into both monolayers. The XR curves for the lipid/
peptide films were also fitted using a three-slab model
(Table 1). In both films, ~30% of the CpreTM peptide’s
TABLE 1 Results of x-ray reflectivity data analysis




extra total s (A˚) L
T (A˚) A (A˚2) L:P100 L:P50 Apeptide (A˚2)
DPPC/cholesterol (87:13)
DPPCAC þ CHOLAC 7.9 0.311 NA NA NA 3.35 0.2 24.3 47.7 NA NA NA
DPPCAC þ CHOLRB 7.5 0.331
DPPCHG þ CHOLHG 8.9 0.424
DPPC/cholesterol (87:13) þ CpreTM
DPPCAC þ CHOLAC þ CpreTM 7.9 0.278 0.273 2.2 57.1 2.75 0.2 25.2 54.4 43:1 38:1 255–288
DPPCAC þ CHOLRB þ CpreTM 7.4 0.326 0.294 12.9
DPPCHG þ CHOLHG þ CpreTM 9.9 0.412 0.334 42
DPPC/cholesterol (54:46)
DPPCAC þ CHOLAC 7.5 0.281 NA NA NA 3.15 0.2 24.5 40.9 NA
DPPCAC þ CHOLRB 9.9 0.359
DPPCHG þ CHOLHG 7.1 0.417
DPPC/cholesterol (54:46) þ CpreTM
DPPCAC þ CHOLAC þ CpreTM 6.0 0.279 0.279 0 96.1 3.35 0.7 24.9 51.5 25:1 22:1 233–265
DPPCAC þ CHOLRB þ CpreTM 9.6 0.347 0.294 26.2
DPPCHG þ CHOLHG þ CpreTM 9.3 0.399 0.253 69.9
AC, acyl chains; RB, ring body of cholesterol; HG, headgroups; L, slab thickness; r exp, experimental average electron density of a slab; r est, estimated
average electron density of a slab; eextra, number of extra electrons in a slab; e

extra total, total number of extra electrons in a film; L
T, total thickness of
the film; A, area/average lipid molecule; L:P100 and L:P50, lipid/peptide ratios assuming 100% and 50% hydration of peptide polar groups; Apeptide, estimated
area/peptide molecule.
MPER Activity Dependence on Cholesterol 2431mass penetrates into the hydrophobic core of the lipid, and
the rest localizes in the lipid HGs. Consistent with similar
topologies, a 1.7-fold decrease in the lipid/peptide ratio in
the CpreTM/(54:46) mixed monolayer system as compared
to CpreTM/(87:13) mixed film system is matched by even
1.7-1.8 times increase in peptide’s electrons in the lipid
hydrophobic and HG regions. In addition, the observed
increase in monolayer thickness upon peptide insertion,
mainly localized at the HG slab, supports that CpreTM
interactions preferentially occur within this monolayer
region. By comparison, at similar monolayer peptide doses,
the AMP LL-37 mainly localized within the hydrocarbon-
core and provoked a significant reduction in the layer
thickness (41).
Our conclusions about the depth of peptide penetration
into the mixed monolayers are further indirectly supported
by the GIXD data (Table 2). The diffraction of DPPC/
cholesterol monolayers is due to the lipid hydrophobic
region (DPPC acyl chains and cholesterol rigid fused ring
body). Therefore, should the peptide insert mainly into the
lipid HGs, it would create voids in the monolayer hydro-
phobic region, resulting in a less dense packing of the acyl
chains and cholesterol molecules in the ordered domains.
On the other hand, if a peptide penetrates deep into the
film hydrophobic core, it may create additional stress on
the lipid acyl chains and force them to pack more densely.TABLE 2 GIXD data
Experiment d-Spacing (A˚) Unit cell parameters
13:87 d(1,1),(1,1) ¼ 4.55 d(0,2) ¼ 4.30 a ¼ 5.37,
þ CpreTM d(1,1),(1,1) ¼ 4.59 d(0,2) ¼ 4.28 a ¼ 5.44, b
46:54 4.69 a ¼ b ¼
þ CpreTM 4.7 a ¼ b ¼Indeed, Table 2 indicates that CpreTM insertion leads to
an increase in the unit cell area of the crystalline domains
of both monolayers. It is noteworthy that CpreTM was not
capable of disrupting the in-plane order of the mixed mono-
layers completely, as follows from the preserved diffraction
peaks (Fig. S3). This again is opposite to the effect reported
for the AMP LL-37 peptide (41). After LL-37 insertion, no
Bragg peaks or rods could be observed, consistent with the
total disruption by the peptide of the ordered structure of the
monolayer (41).
In conclusion, CpreTM peptide interacted favorably with
Chol-containing lipid monolayers, and its topology was not
significantly altered upon increasing the concentration of
this compound. In addition, it did not display monolayer-
disrupting activities as those described for AMPs (41,42).DISCUSSION
Early Wimley-White interfacial hydrophobicity computa-
tion, together with partitioning experiments (7), supported
the model of MPER insertion into the viral membrane inter-
face (Fig. 1 A, left). It was further proposed that the shallow
insertion of MPER into the envelope external leaflet might
poise the viral membrane for fusion (7,43). However, those
estimates did not take into consideration the high Chol
concentration at the viral membrane (15). Phospholipida and b (A˚), g (), and area A (A˚2) Coherence length (A˚)
b ¼ 8.6, g ¼ 90, A ¼ 46.2 L(1,1),(1,1) ¼ 52; L(0,2) ¼ 301
¼ 8.56, g ¼ 90, A ¼ 46.6 L(1,1),(1,1) ¼ 19; L(0,2) ¼ 158
5.41, g ¼ 120, A ¼ 25.3 58
5.42, g ¼ 120, A ¼ 25.5 22
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the opening of cavities required for transferring MPER resi-
dues into the biologically relevant viral membrane (18).
Viral Chol levels would in addition alter the bilayer mechan-
ical properties to oppose MPER-induced restructuring
(17,33,34,44). In line with the phospholipid-condensing
properties of the compound, Chol reduced partitioning
into vesicles of MPERp, the peptide so far considered to
be representative of the MPER domain (Figs. 2 and 3).
Also consistent with the lack of interaction with the Chol-
enriched viral membrane, the infectivity experiments re-
vealed a low, but HIV-specific, MPERp-induced inhibition,
which points to the gp41 protein, rather than the lipid enve-
lope, as the target for this peptide (Fig. 4). Impeded insertion
into the viral membrane and restrained deformability would
be consistent with an alternative model proposing that
MPER remains associated to the gp41 globular ectodomain
(Fig. 1 A, right), both in the native glycoprotein and during
fusion (13).
However, the MPER-TMD LWYIK-LFIMIV hinge
sequence represents an important gp41 functional determi-
nant (4,11,30) not included in the MPERp peptide sequence.
The CpreTM peptide used in this study was actually
conceived to preserve the sequence environment of this
determinant (Fig. 1 B). We report here Chol effects on
peptide-membrane interactions that are comparatively
different for MPERp and CpreTM. In fact, our data support
an adaptation of the gp41 sequence represented by CpreTM
for inserting into and destabilizing the rigid viral envelope.Implications of CpreTM-lipid interactions
for MPER insertion into the viral membrane
The increase in phospholipid cohesion that ensues with high
concentrations of Chol did not inhibit CpreTM partitioning
(Figs. 2 and 3), which might reflect the capacity of this se-
quence for inserting into the viral envelope. In support of
this assumption, infectivity of HIV virions was effectively
inhibited by CpreTM (Fig. 4). Of note, VSV-G-mediated
cell infection was inhibited by this peptide to the same
extent. The lack of specificity observed in these experiments
is highly suggestive of a CpreTM-induced inhibition mech-
anism involving insertion into the viral membrane, i.e.,
following a pattern similar to that of antiviral compounds
that target a broad range of unrelated enveloped viruses
(35,36). Effective CpreTM insertion into Chol-enriched
membranes was further confirmed using lipid monolayers.
The use of this system allowed us to imitate the in vivo
situation when MPER putatively comes into contact with
the outer leaflet of the virion membrane. XR data for
monolayers containing CpreTM and different Chol concen-
trations did not reveal significant changes in peptide
topology, whereas the area occupied by the peptide at the
interface was smaller in monolayers with high Chol content
(Table 1). This reduction of the monolayer area occupied byBiophysical Journal 101(10) 2426–2435the peptide implies smaller membrane cavities to accommo-
date peptide residues and, therefore, optimization of the
energy cost for membrane insertion (18).
A recent study by Tristam-Nagle and co-workers (32)
has provided an additional explanation for the CpreTM
capacity for inserting into Chol-enriched membranes. Their
x-ray synchrotron scattering data indicate that the LWYIK
sequence may counteract the chain-ordering effect caused
by Chol. Thus, we speculate that tethering to the gp41
TMD N-terminus enables LWYIK insertion into the Chol-
enriched external monolayer of the viral membrane, which
may then reduce phospholipid cohesion therein. This effect
might also enable insertion of CpreTM, even with Chol
concentrations in the range of 50 mol %. Altogether, the
experimental evidence presented in this work and previous
x-ray structural determinations suggest that the MPER-
TMD gp41 region represented by CpreTM may favorably
associate with the viral membrane (Fig. 1 A, left).Implications of CpreTM-lipid interactions
for viral membrane perturbation by MPER
Consistent with the CpreTM capacity for perturbing the
rigid viral membrane upon insertion, leakage induced by
the peptide was stimulated by Chol (Figs. 3 and 5). It has
been reported that membrane permeabilization after treat-
ment of the virus with Chol-binding b-cyclodextrin actually
abolishes HIV infectivity (45). Notably, this compound was
effective in the millimolar range of concentrations (IC50 of
~3 mM in our assay (not shown)). Thus, the fact that the
IC50 values measured for CpreTM are three to four orders
of magnitude lower underlines its higher potency and sug-
gests a different mechanism of action.
The low peptide doses required for permeabilizing Chol-
containing vesicles (Fig. 5 B and Table S1) rather suggest
that CpreTM generates true pores in the viral membrane.
Assembly of discrete aqueous pores is further supported by
the all-or-none mechanism of lekage observed in LUVs
(Fig. 5C) and giant vesicles (46) that containChol. In the latter
system, CpreTMwas actually shown to establish permanently
opened pores (46). All-or-none leakage induced by true pore-
forming peptides has been subject to mathematical analysis
based on a pore model that takes into account aggregation
reversibility of peptide monomers at the membrane surface
(38). A preliminary analysis of the CpreTM-induced leakage
data (Fig. 5 B) displayed good fits to this model (Table S1).
Finally, the results of GIXD experiments, which indicate
that CpreTM insertion did not disrupt the in-plane order of
the lipid monolayers (Table 2 and Fig. S3) would also be
consistentwith the assemblyofCpreTMtruepores inChol-en-
richedmembranes. In contrast, interfacially activeAMPs (37),
such as LL-37 or protegrin-1, destabilize lipid packing and
produce disruption of monolayers upon insertion (41,42).
In conclusion, CpreTM exhibits features of a true
pore-forming peptide modulated by Chol. However, this
MPER Activity Dependence on Cholesterol 2433phenomenon would be at odds with the lack of lipid selec-
tivity postulated for the potent, ideal pore-forming peptides
(37). Lipid modulation of the process is often ascribed to the
formation of toroidal, lipidic pores (37,47). To establish
a lipidic pore, the bilayer must bend and deform so that lipid
HGs interspersed with peptide units line the walls of a
toroidal aqueous channel (17,48,49). Peptides forming
lipidic pores induce monolayer area expansion and concom-
itant thinning (18,47). Our XR data indicate opposite effects
for CpreTM interacting with monolayers (Table 1). In both
monolayers, peptide insertion resulted in an increase of the
monolayer thickness. In addition, the area occupied by the
peptide was reduced in the monolayer containing high levels
of Chol, i.e., under conditions of optimal pore formation.
Given the geometry of the toroid, permeabilization accord-
ing to this mechanism is distinctively promoted by lipids
that impart a positive spontaneous curvature (1/R0) to the
bilayer (17,49). As compared to Chol, including into the
bilayer composition LPC or DG, two lipids with known
positive and negative spontaneous curvatures, respec-
tively, had little effect on CpreTM binding or vesicle perme-
abilization (Fig. S4). Thus, it appears that CpreTM did not
promote lipidic pore formation in the Chol-enriched
membranes.
Previous structural characterizations of the LWYIK se-
quence by Epand and colleagues provide a putative molec-
ular mechanism to explain Chol effects on CpreTM-induced
leakage (30,31). These authors have proposed that LWYIK
sequence may directly bind to and sequester Chol (31).
Based on calculations of the most favorable conformations
it was inferred that LWYIK interactions with Chol would
occur at the membrane interface and involve H-bonding of
its hydroxyl group (31). The observed increase in monolayer
HG slab thickness upon peptide insertion would actually
support such an interaction for CpreTM (Table 1). Satis-
fying polar head requirements set Chol rings rather free
for intermolecular interactions. We surmise that this interfa-
cial interaction may first prevent deep insertion of the
CpreTM sequence into the acyl-chain region of the bilayer
and then drive self-association of peptides and Chol. Thus,
we infer that the local increase of the CpreTM concentration
in the Chol-containing membranes might promote pore
formation by this peptide.CONCLUDING REMARKS: IMPLICATIONS FOR
ANTI-HIV VACCINE AND INHIBITOR
DEVELOPMENT
Altogether, the experimental evidence reported in this
work suggests that the MPER region represented by the
CpreTM peptide is adapted for bilayer binding and destabi-
lization under the conditions existing in the HIV envelope
milieu, i.e., low spike density (10–20 trimers/virion) (5)
and high Chol content (~45 mol %) (15). In contrast, the
MPERp peptide was unable to reproduce the binding andmembrane-perturbing activities attributed to the functional
MPER domain. In addition, we provide data indicating
that CpreTM might perturb viral membrane integrity
through the establishment of discrete aqueous pores. These
observations might have important implications for devel-
opment of anti-HIV inhibitors and immunogens. On one
hand, the functional sequence of MPER should be redefined
to include the TMDN-terminus. On the other hand, CpreTM
pore structures assembled in Chol-enriched membranes
seem to represent an unprecedented, biologically relevant
MPER target.
Thus, the CpreTM sequence embodies a new scaffold,
prospectively useful for expanding the spectrum of antiviral
drugs targeting the membranes of enveloped viruses (35,36).
In particular, CpreTM-based compoundsmight be devised to
target viral membranes enriched in Chol. Moreover,
mimicking the epitope recognized by the broadly neutral-
izing 4E10 antibody by model systems (Fig. 1) constitutes
a timely goal for the development of effective anti-HIV
immunogens (29,50). In that regard, our data suggest that
the native structures adopted by this MPER sequence on
the surface of the viral envelope might depend on the
MPER-TMD hinge region and Chol.SUPPORTING MATERIAL
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